Treatment of febrile neutropenia is expensive: Prevention is the answer

Onkologie

Volumn 34, Issue 5, 2011, Pages 226-228

  Klastersky, Jean A ^a   Paesmans, Marianne ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBIOTIC THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; EDITORIAL; FEBRILE NEUTROPENIA; HUMAN; INTENSIVE CARE; LYMPHOMA; PROPHYLAXIS; SOLID TUMOR;

EID: 79957491207     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000327818     Document Type: Editorial

References (17)

1. Klastersky J, Awada A, Paesmans M, et al.: Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2010 DOI: 10.1016/j.critrevonc. 2010.03.008.
2. Weycker D, Malin J, Edelsberg J, et al.: Cost of neutropenic complications of chemotherapy. Ann Oncol 2008;19:454-460. (Pubitemid 351325664)
3. Klastersky J, Paesmans M, Rubenstein EB, et al.: The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051. (Pubitemid 30644129)
4. Klastersky J, Paesmans M, Georgala, A et al.: Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006;24:4129-4134. (Pubitemid 46622289)
5. Innes HE, Smith DB, O'Reilly SM, et al.: Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Brit J Cancer 2003;89:43-49. (Pubitemid 36897933)
6. Cullen M, Steven N, Billingham L, et al.: Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353: 988-998. (Pubitemid 41262333)
7. Bucaneve G, Micozzi A, Menichetti F, et al.: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-987. (Pubitemid 41262332)
8. Kuderer NM, Dale DC, Crawford J, et al.: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2008;25:3158-3167. (Pubitemid 47218066)
9. Crawford J, Ozer H, Stoller R, et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients will small-cell lung cancer. N Engl J Med 1991;325:164-170.
10. Aapro MS, Cameron DA, Pettengell R, et al.: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-2453. (Pubitemid 44442936)
11. Klastersky J, Georgala A, Ameye L, et al.: Febrile neutropenia occurring in patients with solid tumors: is the risk of complications affected by the type of chemotherapy? Support Care Cancer 2010;18 (suppl 3): S101.
12. Klastersky J, Awada A, Aoun M, et al.: Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? Curr Opin Oncol 2009;21: 297-302.
13. Ihbe-Heffinger A, Paessens BJ, von Schilling C, et al.: Management of febrile neutropenia - a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer and primary breast cancer. Onkologie 2011;34: DOI: 10.1159/000327711.
14. Lyman G, Lalla A, Barron R, et al.: Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009;25:401-411.
15. Ramsey SD, Liu Z, Boer R, et al.: Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy: Value Health 2009;12: 217-225.
16. Papaldo P, Lopez M, Marolla P, et al.: Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005;28: 6908-18.
17. Morrison VA, Wong M, Hershman D, et al.: Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337-48. (Pubitemid 46958752)